{"id":156029,"date":"2021-10-05T18:19:05","date_gmt":"2021-10-05T22:19:05","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/celsion-corporation-adds-key-resources-to-its-vaccine-development-initiative-and-clinical-trial-capabilities\/"},"modified":"2024-08-18T11:43:29","modified_gmt":"2024-08-18T15:43:29","slug":"celsion-corporation-adds-key-resources-to-its-vaccine-development-initiative-and-clinical-trial-capabilities","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/celsion-corporation-adds-key-resources-to-its-vaccine-development-initiative-and-clinical-trial-capabilities.php","title":{"rendered":"Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities"},"content":{"rendered":"<p><![CDATA[LAWRENCEVILLE, N.J., Oct.  05, 2021  (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as follows:]]><\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/10\/05\/2308813\/0\/en\/Celsion-Corporation-Adds-Key-Resources-to-its-Vaccine-Development-Initiative-and-Clinical-Trial-Capabilities.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities\">Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See original here: Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/celsion-corporation-adds-key-resources-to-its-vaccine-development-initiative-and-clinical-trial-capabilities.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-156029","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156029"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=156029"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156029\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=156029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=156029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=156029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}